ARQ 501 in Subjects With Cancer

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)80 enrolled

Overview

ARQ 501, an investigational anticancer drug, is intended to selectively kill cancer cells and spare normal cells by restoring and activating cellular checkpoints known to be defective in cancer using the Company's unique biology platform, Activated Checkpoint Therapy™ (ACT). ARQ 501 has the potential for improved activity and reduced toxicity over other molecular approaches and traditional cancer chemotherapy.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Cancer

Interventions

ARQ 501DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria * Histologically or cytologically confirmed solid tumor that is metastatic, unresectable or recurrent and for which standard curative or palliative measures do not exist or are no longer effective. * ECOG performance status greater than or equal to 1 * Life expectancy greater than three months * Acceptable pretreatment clinical laboratory results Exclusion Criteria * Subjects who have had chemotherapy or radiotherapy within 4 weeks * Subjects receiving any other investigational agents * Subjects with known untreated brain metastases * Subjects receiving hepatic enzyme-inducing antiseizure drugs ("EIASD") * Subjects with uncontrolled intercurrent illnesses * Pregnant women

Locations (2)

Dana Farber/Partners CancerCare Inc

Boston, Massachusetts, United States

Mary Crowley Medical Research Center

Dallas, Texas, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.